Two new weapons for defending Hatch-Waxman litigation
Mark Remus of Brinks Gilson & Lione discusses two patent-related challenges for generic pharmaceutical companies and how they might be overcome.
LSIPR 50 2018: Christopher Viehbacher
Christopher Viehbacher was selected in the LSIPR 50 2018 publication for his influence on the life sciences industry. He featured in the investment section, as LSIPR reports.
LSIPR 50 2018: Iana Dimkova
Iana Dimkova was selected in the LSIPR 50 2018 publication for her influence on the life sciences industry. She featured in the investment section, as LSIPR reports.
LSIPR 50 2018: Jean-François Formela
Jean-François Formela was selected in the LSIPR 50 2018 publication for his influence on the life sciences industry. He featured in the investment section, as LSIPR reports.
LSIPR 50 2018: Frank Kalkbrenner
Frank Kalkbrenner was selected in the LSIPR 50 2018 publication for his influence on the life sciences industry. He featured in the investment section, as LSIPR reports.
LSIPR 50 2018: Bryan Roberts
Bryan Roberts was selected in the LSIPR 50 2018 publication for his influence on the life sciences industry. He featured in the investment section, as LSIPR reports.
LSIPR 50 2018: Jim Tananbaum
Jim Tananbaum was selected in the LSIPR 50 2018 publication for his influence on the life sciences industry. He featured in the investment section, as LSIPR reports.
LSIPR 50 2018: Craig Muir
Craig Muir was selected in the LSIPR 50 2018 publication for his influence on the life sciences industry. He featured in the investment section, as LSIPR reports.
SPC export waiver: a long road ahead
The European Commission’s proposed export waiver for supplementary protection certificates is likely to face opposition and may be delayed by EU parliamentary changes, says Trevor Cook of WilmerHale.
LSIPR 50 2018: Brian Anderson
Brian Anderson was selected in the LSIPR 50 2018 publication for his influence on the life sciences industry. He featured in the legal section, as LSIPR reports.
